Format

Send to

Choose Destination
Curr Opin Mol Ther. 2007 Aug;9(4):353-63.

Treating HIV-1 infection with dendritic cells.

Author information

1
University of Pittsburgh, School of Medicine and Graduate School of Public Health, 204 Craft Avenue, B501, Pittsburgh, PA 15213, USA. nconnolly@mail.magee.edu

Erratum in

  • Curr Opin Mol Ther. 2007 Oct;9(5):515.

Abstract

The orchestration of a coordinated immune response by dendritic cells (DCs) make them an attractive target for pathogens to exploit to evade host immunity, as well as for use in therapeutic strategies to overcome this exploitation. Because HIV-1 infection is predominantly a disease of the immune system, targeting DCs for therapeutic strategies to counter the effects of HIV-1 on DCs and other immune effector cells is a timely and extremely dynamic endeavor. Our knowledge of DC function and the interaction between HIV-1 and DCs is rapidly increasing. This review focuses on HIV-1-DC interactions, the impact of these on DC therapeutics for the treatment of HIV-1-infected individuals and the current status of DC-based therapeutic vaccines for HIV-1 infection.

PMID:
17694448
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center